AstraZeneca's Covid-19 vaccine candidate begins late-stage US study

(Reuters) - AstraZeneca Plc said on Monday it has begun enrolling adults for a U.S.-funded, 30,000-subject late-stage study of its high profile COVID-19 vaccine candidate. Trial participants will receive either two doses of the experimental vaccine, dubbed AZD1222, four weeks apart, or a placebo, the company said. The trial is being conducted under U.

S. government's Operation Warp Speed program, which aims to accelerate development, manufacturing and distribution of vaccines and treatments for COVID-19. U.S. President Donald.

This article is no longer available in our repository.

There could be multiple reasons for this.